De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry

BACKGROUND: Limited data exist describing real‐world treatment of de novo and recurrent HER2‐positive metastatic breast cancer (MBC). MATERIALS AND METHODS: The Systemic Therapies for HER2‐Positive Metastatic Breast Cancer Study (SystHERs) was a fully enrolled (2012–2016), observational, prospective...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Principais autores: Tripathy, Debu, Brufsky, Adam, Cobleigh, Melody, Jahanzeb, Mohammad, Kaufman, Peter A., Mason, Ginny, O'Shaughnessy, Joyce, Rugo, Hope S., Swain, Sandra M., Yardley, Denise A., Chu, Laura, Li, Haocheng, Antao, Vincent, Hurvitz, Sara A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7011632/
https://ncbi.nlm.nih.gov/pubmed/32043771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0446
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados